Diadexus, Inc. Stock

DDXSQ

US25245P2056

Pharmaceuticals

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

17/09/21	Diadexus, Inc. Went Out of Business	CI
08/06/18	Motion for Asset Sale Approved for Diadexus, Inc.	CI

Diadexus, Inc. is a diagnostics company. The Company is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of patients throughout the course of cardiac disease. Its capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearance, and marketing and selling products. Its commercially-available products consist of two FDA-cleared tests to measure Lp-PLA2: the PLAC Test ELISA Kit (the PLAC ELISA Test) and the PLAC Test for Lp-PLA2 Activity (the PLAC Activity Test). Its other products include proADM; proET-1, which aids in predication of heart failure, and proANP, which aids in predication of heart failure. The Company sells its diagnostic products to laboratories and promotes these products to the laboratories' sales representatives, as well as directly to healthcare providers.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	49.2K 42.4K 39.75K 36.29K 68.36K 4.7M 68.57K 472K 184K 2.37M 185K 181K 7.87M	P/E 2014	-3.26x	P/E 2015	-1.14x
Enterprise Value	5.29M 4.56M 4.27M 3.9M 7.35M 506M 7.37M 50.71M 19.78M 255M 19.86M 19.43M 846M	EV / Sales 2014	1.05x	EV / Sales 2015	0.77x
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

17/09/21	Diadexus, Inc. Went Out of Business	CI
08/06/18	Motion for Asset Sale Approved for Diadexus, Inc.	CI
09/05/18	Motion for Asset Sale Filed by Diadexus, Inc.	CI
01/08/16	Diazyme Laboratories, Inc. completed the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
29/07/16	Motion for Asset Sale Approved for Diadexus, Inc.	CI
29/07/16	General Atomics Corp. entered into purchase agreement to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $4.8 million.	CI
20/07/16	Cleveland HeartLab, Inc. cancelled the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
07/07/16	Motion for Asset Sale Filed by Diadexus, Inc.	CI
07/07/16	Cleveland HeartLab, Inc. agreed to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $7 million.	CI
13/06/16	Diadexus, Inc. Filed for Bankruptcy	CI
11/06/16	Diadexus, Inc. Announces Resignation of Leone Patterson as Chief Financial Office	CI
23/05/16	Diadexus, Sonic Healthcare USA Sign National Agreement for PLAC Activity Test	CI
30/04/16	Diadexus, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DIADEXUS, INC.	-.--%	-.--%	-	-	410
ULTRAGENYX PHARMACEUTICAL INC.	-2.48%	-0.85%	-15.48%	-30.18%	2.58B
SAREPTA THERAPEUTICS, INC.	-3.38%	+11.02%	+13.74%	-82.41%	2.28B
BIONOTE, INC.	+1.05%	-0.83%	-14.59%	-3.32%	348M
DK LIFE SCIENCE CO., LTD.	+1.79%	+2.24%	-46.42%	-	51.86M
Average	-0.60%	+2.94%	-15.69%	-38.64%	1.05B
Weighted average by Cap.	-2.59%	+6.98%	-3.06%	-51.25%

	2014	2015
Net sales	26.11M 22.5M 21.1M 19.26M 36.28M 2.5B 36.39M 250M 97.66M 1.26B 98.04M 95.9M 4.18B	17.88M 15.41M 14.45M 13.19M 24.85M 1.71B 24.93M 171M 66.88M 863M 67.15M 65.68M 2.86B
Net income	-8.47M -7.3M -6.84M -6.24M -11.76M -809M -11.8M -81.16M -31.67M -408M -31.79M -31.1M -1.35B	-7.17M -6.17M -5.79M -5.29M -9.96M -685M -9.99M -68.69M -26.8M -346M -26.9M -26.32M -1.15B
Net Debt	-198K -171K -160K -146K -275K -18.92M -276K -1.9M -741K -9.55M -743K -727K -31.67M	5.24M 4.52M 4.23M 3.87M 7.28M 501M 7.3M 50.24M 19.6M 253M 19.68M 19.25M 838M

Diadexus, Inc. Stock

Stocks

DDXSQ

US25245P2056

Pharmaceuticals

Valuation : Diadexus, Inc.

Latest news : Diadexus, Inc.

Diagnostic & Testing Substances Manufacturers

Financials

Company Profile